


**Product Name** : Roflumilast  
**Cat. No.** : PC-20681  
**CAS No.** : 162401-32-3  
**Molecular Formula** : C<sub>17</sub>H<sub>14</sub>Cl<sub>2</sub>F<sub>2</sub>N<sub>2</sub>O<sub>3</sub>  
**Molecular Weight** : 403.21  
**Target** : Phosphodiesterase (PDE)  
**Solubility** : 10 mM in DMSO



CAS: 162401-32-3

## Biological Activity

Roflumilast (APTA-2217) is a potent, selective, orally active PDE4 inhibitor with IC<sub>50</sub> of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDE4A4, PDEB1, and PDEB2, respectively.

Roflumilast shows no PDE4 subtype selectivity apart from PDE4C (4C1, IC<sub>50</sub>=3 nM; 4C2, IC<sub>50</sub>=4.3 nM), does not inhibit PDE1, PDE2, PDE3 or PDE5 isoenzymes.

Roflumilast inhibits human neutrophil functions, inhibits TNF $\alpha$  synthesis in monocyte-derived dendritic cells.

Roflumilast inhibits proliferation and cytokine synthesis in CD4<sup>+</sup> T cells.

Roflumilast inhibits the ovalbumin-evoked contractions of tracheal chains prepared from sensitized guinea pigs with EC<sub>50</sub> of 0.2  $\mu$ M.

Roflumilast abrogated LPS-induced circulating TNF $\alpha$  in the rat (ED<sub>50</sub>) = 0.3 micromol/kg) in bronchoalveolar lavage fluid of Brown Norway rats.

## References

Bundschuh DS, et al. J Pharmacol Exp Ther. 2001 Apr;297(1):280-90.

Hatzelmann A, et al. J Pharmacol Exp Ther. 2001 Apr;297(1):267-79.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com